Combined Modality Therapy for Gastric, Pancreatic, and Biliary Tract Carcinomas

  • Alexandria Phan
  • Jaffer A. Ajani
Part of the Cancer Drug Discovery and Development book series (CDD&D)


Localized cancers are not often treated using a single modality. Rather, they are approached in a multidisciplinary manner. This approach has evolved over the past 15 yr to include medicine, surgery, radiation oncology, and gastroenterology.


Gastric Cancer Pancreatic Cancer Curative Resection Pancreatic Carcinoma Gallbladder Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Anonymous, SEER Cancer Statistics Review, 1973–98. 1998.Google Scholar
  2. 2.
    Neugut AI, Hayek M, Howe G. Epidemiology of gastric cancer. Semin Oncol 1996; 23 (3): 281–291.PubMedGoogle Scholar
  3. 3.
    Gonzalez CA, et al. Occupation and gastric cancer in Spain. Scand J Work Environ Health 1991; 17 (4): 240–247.PubMedCrossRefGoogle Scholar
  4. 4.
    Kneller RW, et al. Occupational risk factors for gastric cancer in Shanghai, China. Am J Ind Med 1990; 18 (1): 69–78.PubMedGoogle Scholar
  5. 5.
    Parent ME, Siemiatycki J, Fritschi L. Occupational exposures and gastric cancer. Epidemiology 1998; 9 (1): 48–55.PubMedCrossRefGoogle Scholar
  6. 6.
    Tsuda T, et al. A case-control study of the relationships among silica exposure, gastric cancer, and esophageal cancer. Am J Ind Med 2001; 39 (1): 52–57.PubMedCrossRefGoogle Scholar
  7. 7.
    Sugimura T, Matsukura N, Sato S. Intestinal metaplasia of the stomach as a precancerous stage. IARC Sci Publ 1982; 39: 515–530.PubMedGoogle Scholar
  8. 8.
    Lei DN, Yu JY. Types of mucosal metaplasia in relation to the histogenesis of gastric carcinoma. Arch Pathol Lab Med 1984; 108 (3): 220–224.PubMedGoogle Scholar
  9. 9.
    Brennan MF, Karpeh MS Jr. Surgery for gastric cancer: the American view. Semin Oncol 1996; 23 (3): 352–359.PubMedGoogle Scholar
  10. 10.
    Bonenkamp JJ, et al. Extended lymph-node dissection for gastric cancer. Dutch Gastric Cancer Group. N Engl J Med 1999; 340 (12): 908–914.PubMedCrossRefGoogle Scholar
  11. 11.
    Cuschieri A, et al. E.A.E.S. multicenter prospective randomized trial comparing two-stage vs single-stage management of patients with gallstone disease and ductal calculi. Surg Endosc 1999; 13 (10): 952–957.PubMedCrossRefGoogle Scholar
  12. 12.
    Cuschieri A, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br Cancer 1999; 79 (9–10): 1522–1530.CrossRefGoogle Scholar
  13. 13.
    Safran H, et al. Paclitaxel and concurrent radiation therapy for locally advanced adenocarcinomas of the pancreas, stomach, and gastroesophageal junction. Seminars in Radiation Oncology 1999; 9 (2 Suppl 1): 53–57.PubMedGoogle Scholar
  14. 14.
    Hermans J, et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 1993; 11 (8): 1441–1447.PubMedGoogle Scholar
  15. 15.
    Earle CC, Maroun A. Adjuvant chemotherapy after curative resection for gastric cancer: Revisiting a meta-analysis of randomized trials (abstract). Proc Am Soc Clin Oncol 1998.Google Scholar
  16. 16.
    Macdonald JS, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345 (10): 725–730.PubMedCrossRefGoogle Scholar
  17. 17.
    Gold EB, Goldin SB. Epidemiology of and risk factors for pancreatic cancer. Surg Oncol Clin NAm 1998; 7 (1): 67–91.Google Scholar
  18. 18.
    Landis SH, et al. Cancer statistics, 1998. (erratum appears in CA Cancer J Clin 1998 May-Jun;48(3):192; CA Cancer J Clin 1998 Nov-Dec;48(6):329). Ca: a Cancer Journal for Clinicians, 1998; 48 (1): 6–29.Google Scholar
  19. 19.
    Wingo PA, et al. Annual report to the nation on the status of cancer, 1973–1996, with a special section on lung cancer and tobacco smoking. J Natl Cancer Inst 1999; 91 (8): 675–690.PubMedCrossRefGoogle Scholar
  20. 20.
    La Vecchia C, et al. Smoking and cancer with emphasis on Europe. Eur J Cancer 1991; 27 (1): 94–104.PubMedCrossRefGoogle Scholar
  21. 21.
    Mack TM, et al. Pancreas cancer and smoking, beverage consumption, and past medical history. J Natl Cancer Inst 1986; 76 (1): 49–60.PubMedGoogle Scholar
  22. 22.
    Olsen GW, et al. A case-control study of pancreatic cancer and cigarettes, alcohol, coffee and diet. Am J Public Health 1989; 79 (8): 1016–1019.PubMedCrossRefGoogle Scholar
  23. 23.
    Silverman DT, et al. Cigarette smoking and pancreas cancer: a case-control study based on direct interviews. J Natl Cancer Inst 1994; 86 (20): 1510–1516.PubMedCrossRefGoogle Scholar
  24. 24.
    Zheng W, et al. A cohort study of smoking, alcohol consumption, and dietary factors for pancreatic cancer (United States). Cancer Causes Control 1993; 4 (5): 477–482.PubMedCrossRefGoogle Scholar
  25. 25.
    Mancuso TF, el-Attar AA. Cohort study of workers exposed to betanaphthylamine and benzidine. J Occup Med 1967; 9 (6): 277–285.PubMedGoogle Scholar
  26. 26.
    Pietri F, Clavel F. Occupational exposure and cancer of the pancreas: a review. Br J Ind Med 1991; 48 (9): 583–587.PubMedGoogle Scholar
  27. 27.
    Hruban RH, et al. Genetics of pancreatic cancer. From genes to families. Surg Oncol Clin NAm 1998; 7 (1): 1–23.Google Scholar
  28. 28.
    Nomoto S, et al. Clinical application of K-ras oncogene mutations in pancreatic carcinoma: detection of micrometastases. Semin Surg Oncol 1998; 15 (1): 40–46.PubMedCrossRefGoogle Scholar
  29. 29.
    Wilentz RE, Hruban RH. Pathology of cancer of the pancreas. Surg Oncol Clin N Am 1998; 7 (1): 43–65.PubMedGoogle Scholar
  30. 30.
    Wingo PA, et al. Cancer incidence and mortality, 1973–1995: a report card for the U.S. Cancer, 1998; 82 (6): 1197–1207.PubMedCrossRefGoogle Scholar
  31. 31.
    Kelsen DP, et al. Pain and depression in patients with newly diagnosed pancreas cancer. J Clin Oncol 1995; 13 (3): 748–755.PubMedGoogle Scholar
  32. 32.
    Krech RL, Walsh D. Symptoms of pancreatic cancer. J Pain Symptom Manage 1991; 6 (6): 360–367.PubMedCrossRefGoogle Scholar
  33. 33.
    Passik SD, Breitbart WS. Depression in patients with pancreatic carcinoma. Diagnostic and treatment issues. Cancer 1996; 78 (3 Suppl): 615–626.PubMedGoogle Scholar
  34. 34.
    Lillemoe KD, Pitt HA. Palliation. Surgical and otherwise. Cancer 1996; 78 (3 Suppl): 605–614.PubMedCrossRefGoogle Scholar
  35. 35.
    Bluemke DA, Fishman EK. CT and MR evaluation of pancreatic cancer. Surg Oncol Clin N Am 1998; 7 (1): 103–124.PubMedGoogle Scholar
  36. 36.
    Fuhrman GM, et al. Thin-section contrast-enhanced computed tomography accurately predicts the resectability of malignant pancreatic neoplasms. Am J Surg 1994; 167(1):104–111; discussion 111–113.CrossRefGoogle Scholar
  37. 37.
    Stevens PD, Lightdale CJ. The role of endosonography in the diagnosis and management of pancreatic cancer. Surg Oncol Clin N Am 1998; 7 (1): 125–133.PubMedGoogle Scholar
  38. 38.
    Fernandez-del Castillo CL, Warshaw AL. Pancreatic cancer. Laparoscopic staging and peritoneal cytology. Surg Oncol Clin N Am 1998; 7 (1): 135–142.PubMedGoogle Scholar
  39. 39.
    Steinberg WM, et al. Workup of a patient with a mass in the head of the pancreas. Pancreas 1998; 17 (1): 24–30.PubMedCrossRefGoogle Scholar
  40. 40.
    Posner MR, Mayer RJ. The use of serologic tumor markers in gastrointestinal malignancies. Hematol Oncol Clin North Am 1994; 8 (3): 533–553.PubMedGoogle Scholar
  41. 41.
    Nakao A, et al. Clinical usefulness of CA-19–9 in pancreatic carcinoma. Semin Surg Oncol 1998; 15 (1): 15–22.PubMedCrossRefGoogle Scholar
  42. 42.
    Ritts RE, Pitt HA. CA 19–9 in pancreatic cancer. Surg Oncol Clin NAm 1998; 7 (1): 93–101.Google Scholar
  43. 43.
    Evans DB, Jessup JM, Colacchio T. Pancreatic cancer surgical practice guidelines. Pancreatic Cancer Practice Guideline Committee. Oncology (Huntingt) 1997; 11 (7): 1074–1079.Google Scholar
  44. 44.
    Nitecki SS, et al. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg 1995; 221 (1): 59–66.PubMedCrossRefGoogle Scholar
  45. 45.
    GITSG, A multi-institutional comparative trial of radiation therapy alone and in combination with 5-fluorouracil for locally unresectable pancreatic carcinoma. The Gastrointestinal Tumor Study Group. Ann Surg 1979; 189 (2): 205–208.Google Scholar
  46. 46.
    GITSG, Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group. Cancer 1987; 59 (12): 2006–2010.CrossRefGoogle Scholar
  47. 47.
    Sohn TA, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000; 4 (6): 567–579.PubMedCrossRefGoogle Scholar
  48. 48.
    Kaiser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985; 120 (8): 899–903.CrossRefGoogle Scholar
  49. 49.
    Klinkenbijl JH, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999; 230(6):776–782; discussion 782–784.Google Scholar
  50. 50.
    Spitz FR, et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 1997; 15 (3): 928–937.PubMedGoogle Scholar
  51. 51.
    Willett CG, et al. Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy. Ann Surg 1993; 217 (2): 144–148.PubMedCrossRefGoogle Scholar
  52. 52.
    Staley CA, et al. Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head. Am J Surg 1996; 171(1):118–124; discussion 124–125.CrossRefGoogle Scholar
  53. 53.
    Griffin JF, et al. Patterns of failure after curative resection of pancreatic carcinoma. Cancer 1990; 66 (1): 56–61.PubMedCrossRefGoogle Scholar
  54. 54.
    Breslin TM, et al. Neoadjuvant chemoradiation for adenocarcinoma of the pancreas. Frontiers Biosci 1998; 3: E193–203.Google Scholar
  55. 55.
    Hoffman JP, et al. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study. J Clin Oncol 1998; 16 (1): 317–323.PubMedGoogle Scholar
  56. 56.
    Pisters PW, et al. Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents. J Clin Oncol 2000; 18 (4): 860–867.PubMedGoogle Scholar
  57. 57.
    Hidalgo M, et al. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J Clin Oncol 1999; 17 (2): 585–592.PubMedGoogle Scholar
  58. 58.
    Lawrence TS, et al. Radiosensitization of pancreatic cancer cells by 2’,2’-difluoro-2’-deoxycytidine. Int J Radiat Oncol Biol Phys 1996; 34 (4): 867–872.PubMedCrossRefGoogle Scholar
  59. 59.
    Miller AR, et al. Neoadjuvant chemoradiation for adenocarcinoma of the pancreas. Surg Oncol Clin N Am 1998; 7 (1): 183–197.PubMedGoogle Scholar
  60. 60.
    Robertson JM, Shewach DS, Lawrence TS. Preclinical studies of chemotherapy and radiation therapy for pancreatic carcinoma. Cancer 1996; 78 (3 Suppl): 674–679.PubMedGoogle Scholar
  61. 61.
    Yamaguchi K, Tsuneyoshi M. Subclinical gallbladder carcinoma. Am J Surg 1992; 163 (4): 382–386.PubMedCrossRefGoogle Scholar
  62. 62.
    Oertli DU, Herzog, Tondelli P. Primary carcinoma of the gallbladder: operative experience during a 16 year period. Eur J Surg 1993; 159 (8): 415–420.PubMedGoogle Scholar
  63. 63.
    Fong Y. Aggressive therapy is warranted for gallbladder cancer. Cancer Invest 1998; 16 (1): 64–65.PubMedCrossRefGoogle Scholar
  64. 64.
    de Aretxabala XA, et al. Curative resection in potentially resectable tumours of the gallbladder. Eur J Surg 1997; 163 (6): 419–426.PubMedGoogle Scholar
  65. 65.
    Shepherd HA, et al. Endoscopie biliary endoprosthesis in the palliation of malignant obstruction of the distal common bile duct: a randomized trial. Br J Surg 1988; 75 (12): 1166–1168.PubMedCrossRefGoogle Scholar
  66. 66.
    Andersen JR, et al. Randomised trial of endoscopie endoprosthesis versus operative bypass in malignant obstructive jaundice. Gut 1989; 30 (8): 1132–1135.PubMedCrossRefGoogle Scholar
  67. 67.
    Meyer CG, Penn I, James L. Liver transplantation for cholangiocarcinoma: results in 207 patients. Transplantation 2000; 69 (8): 1633–1637.PubMedCrossRefGoogle Scholar
  68. 68.
    Strong RW. Transplantation for liver and biliary cancer. Semin Surg Oncol 2000; 19 (2): 189–199.PubMedCrossRefGoogle Scholar
  69. 69.
    Wall WJ, Liver transplantation for hepatic and biliary malignancy. Semin Liver Dis 2000; 20 (4): 425–436.PubMedCrossRefGoogle Scholar
  70. 70.
    Bartlett DL, et al. Long-term results after resection for gallbladder cancer. Implications for staging and management. Ann Surg 1996; 224 (5): 639–646.PubMedCrossRefGoogle Scholar
  71. 71.
    Yamamoto M, et al. Recurrence after surgical resection of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg 2001; 8 (2): 154–157.PubMedCrossRefGoogle Scholar
  72. 72.
    de Aretxabala X, et al. Preoperative chemoradiotherapy in the treatment of gallbladder cancer. Am Surg 1999; 65 (3): 241–246.PubMedGoogle Scholar
  73. 73.
    McMasters KM, et al. Neoadjuvant chemoradiation for extrahepatic cholangiocarcinoma. Am J Surg 1997; 174(6):605–608; discussion 608–609.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2003

Authors and Affiliations

  • Alexandria Phan
  • Jaffer A. Ajani

There are no affiliations available

Personalised recommendations